NDAORALSUSPENSION
Approved
Dec 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
ONFI (clobazam) by Lundbeck is cytochrome p450 2d6 inhibitors [moa]. Approved for epilepsy, lennox-gastaut syndrome, seizures. First approved in 2012.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ONFI (clobazam) is an oral benzodiazepine suspension approved by the FDA on December 14, 2012, for the treatment of seizures associated with lennox-gastaut syndrome. As a cytochrome P450 2D6 inhibitor, clobazam works by enhancing GABAergic neurotransmission in the central nervous system. The product is positioned as an adjunctive anti-seizure therapy and represents an important treatment option for patients with this severe, refractory epilepsy syndrome.
$0.0BPart D
Mechanism of Action
Cytochrome P450 2D6 Inhibitors
Pharmacologic Class:
Benzodiazepine
Indications (3)
Worked on ONFI at Lundbeck? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.